Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. (2020)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/ckj/sfz009
PubMed Identifier: 32905262
Publication URI: http://europepmc.org/abstract/MED/32905262
Type: Journal Article/Review
Volume: 13
Parent Publication: Clinical kidney journal
Issue: 4
ISSN: 2048-8505